NASDAQ: CLSDClearside Biomedical Inc Stock
$0.86-0.01 (-1.15%)
Updated Apr 17, 2025
CLSD Price
$0.86
Fair Value Price
$0.17
Market Cap
$66.34M
52 Week Low
$0.70
52 Week High
$1.65
P/E
-1.83x
P/B
-1.71x
P/S
42.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.66M
Earnings
-$34.35M
Gross Margin
91%
Operating Margin
-2,064.42%
Profit Margin
-2,064.4%
Debt to Equity
-1.65
Operating Cash Flow
-$25M
Beta
0.86
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CLSD Overview
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CLSD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CLSD
Ranked#324 of 463
Ranked#324 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important CLSD news, forecast changes, insider trades & much more!
CLSD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CLSD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLSD ($0.86) is overvalued by 409.43% relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CLSD ($0.86) is not significantly undervalued (409.43%) relative to our estimate of its Fair Value price of $0.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CLSD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLSD due diligence checks available for Premium users.
Valuation
CLSD fair value
Fair Value of CLSD stock based on Discounted Cash Flow (DCF)
Price
$0.86
Fair Value
$0.17
Overvalued by
409.43%
CLSD ($0.86) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLSD ($0.86) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLSD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLSD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.83x
Industry
-177.72x
Market
27.98x
CLSD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.71x
Industry
4.05x
CLSD's financial health
Profit margin
Revenue
$306.0k
Net Income
-$7.3M
Profit Margin
-2,387.6%
CLSD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CLSD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$25.1M
Liabilities
$64.0M
Debt to equity
-1.65
CLSD's short-term assets ($21.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLSD's long-term liabilities ($59.19M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLSD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLSD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.3M
Investing
$9.3M
Financing
$2.1M
CLSD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLSD vs Biotech Stocks
Clearside Biomedical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.